Clinical Trial Update: Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating vandetanib (Zactima) in combination with imatinib mesylate and hydroxyurea for recurrent malignant glioma (glioblastoma and gliosarcoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Imatinib mesylate (Imatinib)
• Zactima (vandetanib)

Snippet

Sponsor: Annick Desjardins | Conditions: Glioblastoma, Gliosarcoma | Phase 1 | Status: COMPLETED